Grufity logo
Grufity logo
HOTH

HOTH - Hoth Therapeutics Inc Stock Price, Fair Value and News

$1.12-0.36 (-24.32%)
Market Closed as of 12 Jun 2026, 04:00 pm ET

76/100

HOTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

76/100

HOTH

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOTH Price Action

Last 7 days

-25.8%

Last 30 days

69.7%

Last 90 days

8.7%

Trailing 12 Months

-21.1%

HOTH RSI Chart

HOTH Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

HOTH Valuation

Market Cap

18.2M

Price/Earnings (Trailing)

-1.56

Price/Sales (Trailing)

370.17

Price/Free Cashflow

-1.81

HOTH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

Login to View

Target 6M

Login to View

HOTH Fundamentals

HOTH Revenue

Revenue (TTM)

49.2K

HOTH Earnings

Earnings (TTM)

-11.7M

Earnings Growth (Yr)

22.54%

Earnings Growth (Qtr)

-0.16%

HOTH Profitability

Return on Equity

-280.82%

Return on Assets

-208.9%

Free Cashflow Yield

-55.24%

HOTH Investor Care

Shares Dilution (1Y)

23.54%

Diluted EPS (TTM)

-0.8

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
202449.2K---
202387.4K63.4K49.5K-
2022----
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Hoth Therapeutics Inc

HOTH
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in Phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus, as well as a diagnostic device through a mobile device. The company has license agreements with the George Washington University; Isoprene Pharmaceuticals, Inc.; Virginia Commonwealth University; the North Carolina State University; Chelexa BioSciences, Inc. and the University of Cincinnati; Zylö Therapeutics, Inc.; and Voltron Therapeutics, Inc. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York.
 CEO
 WEBSITEhoththerapeutics.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES2

Hoth Therapeutics Inc Frequently Asked Questions

HOTH is the stock ticker symbol of Hoth Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Fri Jun 12 2026, market cap of Hoth Therapeutics Inc is 18.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Fri Jun 12 2026, HOTH's PE ratio (Price to Earnings) is -1.56 and Price to Sales (PS) ratio is 370.17. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. HOTH PE ratio will change depending on the future growth rate expectations of investors.